HZNP
HORIZON THERAPEUTICS PLC
HORIZON THERAPEUTICS PLC historical holders
total: 5
Abrams Capital Management HORIZON THERAPEUTICS PLC transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2023 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2023 Q3
David Abrams has been an institutional investor in HORIZON THERAPEUTICS PLC (HZNP) since 2023 Q2. According to 2026 Q1 report, David Abrams doesn't hold any shares. The fund/company first acquired HZNP in 2023 Q2, initially purchasing 890,993 shares. Since the initial investment, Abrams Capital Management has made 1 more transaction in this position.
When did David Abrams exit their HZNP position?
David Abrams no longer holds HORIZON THERAPEUTICS PLC (HZNP). They sold off their entire position in 2023 Q3, closing out an investment that began in 2023 Q2.
When did David Abrams first invest in HZNP?
David Abrams first invested in HORIZON THERAPEUTICS PLC (HZNP) in 2023 Q2 at the reported quarter-end price of $102.85 per share, acquiring 890,993 shares in their initial purchase.
What is David Abrams's average cost basis for HZNP?
Based on historical transaction data, David Abrams's estimated cost basis for HORIZON THERAPEUTICS PLC (HZNP) is approximately $102.85 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $102.85
- Weighted AVG sell price:
- $102.85
HZNP transactions history by Abrams Capital Management
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$102.85
|
|
-100% (-890,993)
|
-2.64%
|
|
2023 Q2
|
2.64%
|
890,993
|
$102.85
|
$91,638,630
|
new
|
+2.64%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.